Skip to main content
Log in

EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients

  • Original Research
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

The aim of the study was to analyze the frequency of epidermal growth factor receptor (EGFR) mutations in Brazilian non-small cell lung cancer patients and to correlate these mutations with response to benefit of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Our cohort consisted of prospective patients with NSCLCs who received chemotherapy (platinum derivates plus paclitaxel) at the [UNICAMP], Brazil. EGFR exons 18–21 were analyzed in tumor-derived DNA. Fifty patients were included in the study (25 with adenocarcinoma). EGFR mutations were identified in 6/50 (12 %) NSCLCs and in 6/25 (24 %) adenocarcinomas; representing the frequency of EGFR mutations in a mostly self-reported White (82.0 %) southeastern Brazilian population of NSCLCs. Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 [95 % CI 1.03–90.41], p = 0.047). We report the frequency of EGFR activating mutations in a typical southeastern Brazilian population with NSCLC, which are similar to that of other countries with Western European ethnicity. EGFR mutations seem to be predictive of a response to platinum-paclitaxel, and additional studies are needed to confirm or refute this relationship.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61(2):91–112. doi:10.3322/caaac.20102

    Article  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166

    Article  PubMed  Google Scholar 

  3. Ettinger DS, Akerley W, Borghaei H et al (2012) Non-small cell lung cancer. J Natl Compr Canc Netw 10(10):1236–1271

    CAS  PubMed  Google Scholar 

  4. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  CAS  PubMed  Google Scholar 

  5. Shepherd FA, Rosell R (2007) Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2(Suppl 2):S68–S76

    Article  PubMed  Google Scholar 

  6. Danzinger S, Filipitz M (2007) Biomarkers—the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC). Wien Med Wochenschr 157(21-22):554–561. doi:10.1007/s10354-007-0483-x

    Article  PubMed  Google Scholar 

  7. Ferraldeschi R, Baka S, Jyoti B et al (2007) Modern management of small-cell lung cancer. Drugs 67(15):2135–2152

    Article  CAS  PubMed  Google Scholar 

  8. Lee W, Lockhart AC, Kim RB et al (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104–111. doi:10.1634/theoncologist.10-2-104

    Article  CAS  PubMed  Google Scholar 

  9. Rosell R, Cobo M, Isla D et al (2005) Application of genomics in NSCLC. Lung Cancer S33–40

  10. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550. doi:10.1056/NEJMoa061884

    Article  CAS  PubMed  Google Scholar 

  11. Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol 12:735–742. doi:10.1016/s1470-2045(11)70184-x

    Article  CAS  PubMed  Google Scholar 

  12. De Luca A, Carotenuto A, Rachiglio A et al (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214:559–567

    Article  PubMed  Google Scholar 

  13. Jackman DM, Yeap BY, Sequist LV et al (2006) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12(13):3908–3914. doi:10.1158/1078-0432.CCR-06-0462

    Article  CAS  PubMed  Google Scholar 

  14. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367–1380. doi:10.1056/NEJMra0802714

    Article  CAS  PubMed  Google Scholar 

  15. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73. doi:10.1371/journal.pmed.0020073

    Article  PubMed Central  PubMed  Google Scholar 

  16. Bacchi CE, Ciol H, Queiroga EM et al (2012) Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics (São Paulo, Brazil) 67(5):419–424. doi:10.6061/clinics/2012(05)03

    Article  Google Scholar 

  17. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500. doi:10.1126/science

    Article  CAS  PubMed  Google Scholar 

  18. Johnson BE, Janne PA (2005) Epidermal growth factor receptor mutations in patients with non–small cell lung cancer. Cancer Res 65:7525–7529. doi:10.1158/00085472.CAN-051257

    CAS  PubMed  Google Scholar 

  19. Lin CC, Hsu HH, Sun CT et al (2010) Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. Thorac Oncol 9:1424–1429. doi:10.1097/JTO.ob013e318e9db73

    Article  Google Scholar 

  20. Kim HT, Lee JE, Shin ES et al (2008) Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 26(36):5972–5979. doi:10.1200/JCO.2008.16.6496

    Article  CAS  PubMed  Google Scholar 

  21. Zambon, L (1994) Carcinoma Brônquico: Análise de uma série de casos atendidos no ambulatório de oncopneumologia das disciplinas de Pneumologia e Cirúrgia Torácica da Faculdade de Ciências Médicas da UNICAMP. Dissertation, State University of Campinas (UNICAMP), Brasil.

  22. Dogan S, Shen R, Ang DC et al (2012) Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18(22):6169–6177. doi:10.1158/1078-0432CCR-11-3265

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 36(10):947–957. doi:10.1056/NEJMoa0810699

    Article  Google Scholar 

  24. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. doi:10.1016/s1470-2045(11)70393-x

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank the staff of thoracic surgery at [UNICAMP] for the collection of endobronchial biopsies and Lúcia Helena Siqueira for helping in cloning the technique. This study have been supported by governmental resources from FAPESP (Fundação de Apoio à Pesquisa no Estado de São Paulo), no 09/52574-5.

Conflict of interest

DBC has received consulting fees from Roche and AstraZeneca. The others authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lair Zambon.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Honma, H.N., Perroud, M.W., Leme, M.S.T. et al. EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. Targ Oncol 9, 389–394 (2014). https://doi.org/10.1007/s11523-014-0314-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-014-0314-0

Keywords

Navigation